Chongqing Medical Engineering Institute

Chongqing Pharmaceutical Research Institute (CPRI), also known as the Chongqing Medical Engineering Institute, is a leading pharmaceutical research and development organization based in Chongqing, China. Founded in 1950 and now a key subsidiary of Fosun Pharma, the institute specializes in the development of innovative Class 1 drugs, high-end generic APIs, and advanced formulations. CPRI operates several specialized technology platforms, including chiral drug synthesis, transdermal drug delivery, and taste-masking technologies. The company provides comprehensive CRO and CMC services and has successfully registered numerous products with international regulatory bodies such as the US FDA, EMA, and PMDA. With a strong focus on oncology, CNS, and metabolic diseases, CPRI serves as a critical R&D engine for the Fosun Pharma Group.